Come agisce

Thymuskin® effettua un’azione immunologica sui follicoli grazie all’azione dei peptidi timici di sintesi a basso peso molecolare.

Gli ingredienti biologicamente attivi GKL-02 (brevetto unico al mondo) inibiscono l’azione dei vari enzimi e del DHT che giocano un ruolo fondamentale nelle caduta dei capelli. Questo complesso incrementa l’apporto dei nutrimenti alle cellule della radice del capello (follicolo) durante la fase di crescita (fase anagen) e supporta la formazione di nuove cellule follicolari e rinforza quelle esistenti. Al contempo aumenta la fase di crescita dei capelli. I follicoli che sono rimasti intatti (quindi ancora vitali) vengono riattivati.

banner-dht

Importanti collaborazioni con cliniche ospedaliere e università:

  • Academic Teaching Hospital of the Universities of Frankfurt and Heidelberg
  • City Hospital of Vienna-Lainz, Austria
  • Ruprecht-Karls-University Heidelberg
  • University of Münster
  • Medical Academy Hannover
  • Medical Hospital of the Technical University Munich
  • German Cancer Research Centre Heidelberg
  • Dermatology Unit, University of Milan, Italy
  • Women Dermatologists of Italy (DDI)

Letteratura scientifica sulle applicazioni topiche di Thymuskin® shampoo e serum (lozione)

  1. Clinical study on the effect of a dermocosmetic preparation for local application based on synthetic thymus peptides for alopecia androgenetica and chronic telogen effluvium in women
  2. Topical therapy of androgenetic alopecia with a synthetic peptide library
  3. Thymuskin: New therapy approach for the treatment of alopecia androgenetica and alopecia areata
  4. Local therapy with thymus extract for alopecia areata totalis and universalis
  5. Summary report on the adjuvant local application of Thymuskin preparations in patients undergoing cytostatic chemotherapy
  6. New approaches in the diagnosis and therapy of alopecia in gynaecology
  7. Ludwig Boltzmann Institute for Clinical Oncology Thymuskin Hair Study Part I
  8. Ludwig Boltzmann Institute for Clinical Oncology Thymuskin Hair Study Part II
  9. Prof. Dr. med. Hagedorn Summary field report on the treatment of various forms of alopecia with Thymuskin
  10. Prof. Dr. Claus O. Köhler Different preservation of scalp hair during chemotherapy with various therapeutic agents
  11. Heidelberg University Hospital Women’s Clinic Concluding report on the treatment of alopecia diffusa in women with the local therapeutic agent Thymuskin
  12. Thymuskin: Effectiveness, effects and hypothesis as to the effects
  13. Barbareschi M, Arena N et al.: Multicentric study of the effects of topical lotion and shampoo containing synthetic thymus peptides on androgenetic alopecia and chronic telogen effluvium in women and men. Journal of Plastic Dermatology. 2013: Vol.9
  14. C. Bolduc, J. Shapiro: Management of androgenetic alopecia. Am. J. Clin. Dermat. 2000; 1(3):151-8
  15. Renner D, Schuster D, Heim ME: Experiences using the ‘‘thymu-skin’’ hair cure for the prevention of alopecia in cytostatic treatment. Onkologie (1986) 5:285–
  16. Sawaya ME, Shapiro J: Alopecia – unapproved treatments or indications. Clin Dermatol (2000) 18:177–86
  17. Donne Dermatologhe Italia (DDI). Clinical Investigation of the effects of topical lotion and shampoo containing synthetic thymus peptides on androgenetic and chronic telogen effluvium in women. J Plastic Dermatol 2008; 4:199-205.